GKOS 241220 120.00C (GKOS241220C120000) Stock Options, News & Quotes

US OptionsDetailed Quotes

GKOS241220C120000

Watchlist

18.30
-5.80-24.07%

15min DelayClose Dec 4 16:00 ET

18.30High18.30Low

Intraday

5D
Daily

News

How Is The Market Feeling About Glaukos?
BenzingaDec 3 12:15 ET
Express News | Glaukos Corp - Entered Into Unwind Agreements With Certain Financial Institutions for Capped Call Transactions
ReutersDec 3 06:22 ET
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Seeking AlphaDec 2 16:12 ET
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
BenzingaDec 2 14:29 ET
Glaukos Is Maintained at Buy by Stifel
Dow JonesDec 2 10:37 ET · Ratings
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
BenzingaDec 2 09:05 ET

Comments

Moomoo AI

Jan 21 08:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 01:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...

Meltyy

Dec 4, 2023 01:48

PDUFA Events for December 2023

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$

Moomoo AI

Nov 3, 2023 06:30

Glaukos' stock carries risk due to losses and high debt, despite cash reserves. The absence of EBIT level profits and free cash flow make sustainability questionable. Investors should proceed with caution.

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Rockhoundj

Nov 5, 2022 02:23

Let’s see if this bounces

$Glaukos (GKOS.US)$
im seeing some decent chart upside here
thoughts?